Shares of ImmuPharma plc (LON:IMM – Get Free Report) were up 20.8% on Friday . The stock traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.71 ($0.06). Approximately 16,016,753 shares changed hands during trading, a decline of 26% from the average daily volume of 21,699,041 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Stock Performance
The firm has a market capitalization of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53. The company’s fifty day moving average price is GBX 2.39 and its 200 day moving average price is GBX 1.93.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- The Risks of Owning Bonds
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- 3 Monster Growth Stocks to Buy Now
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- How to Invest in the Best Canadian Stocks
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
